All News
Biomarkers Predictive of a Deucravacitinib Response in Psoriatic Arthritis
A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.
Lupus Research Alliance Grants for Lupus Innovation
d
EurekAlert!
The Lupus Research Alliance (LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA).
Read Article
Window of Opportunity in Psoriatic Arthritis
The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome.
No Link Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance
Annals of Internal Medicine reports a study of more than 75,000 persons screened for monoclonal gammopathy of undetermined significance (MGUS) and found no association between autoimmune rheumatic disease (AIRD) and MGUS.
SLE Cost of Care and Disease Activity
A longitudinal, multinational study shows that SLE patients achieving remission or low disease activity incur lower overall direct/indirect (DCs, ICs) healthcare costs than those with persistent activity.
https://t.co/Rk7SNpHaKu https://t.co/yvJ4qw1YCJ
Dr. John Cush RheumNow ( View Tweet)
Lille Univ Hosp study of 485 systemic sclerosis pts, found osteoporosis in 23% (18% w/ fragility Fx). OP independently linked to age (OR1.06), topoisomerase I Ab+ positivity (OR 2.22) & GC treatment (OR 4.48) https://t.co/9KN5VQnl4A https://t.co/L7RwDdzaFZ
Dr. John Cush RheumNow ( View Tweet)
Greek cohort study of 570 SLE pts; lupus nephritis was initial presentation in 59, w/ another 66 LN during F/U (total LN= 22%). Predictors of LN: male sex (adjHR 4.31), Dx age <26yrs (3.71), Hi dsDNA (2.48), low C3/C4 (NS 2.24) https://t.co/lGmZlBpaPq https://t.co/XLqODDTnX6
Dr. John Cush RheumNow ( View Tweet)
"Don't You Know Who I am?" (5.17.2024)
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?
https://t.co/oH5qdTvGY9 https://t.co/gTqIKemvOu
Dr. John Cush RheumNow ( View Tweet)
Australian multicenter KARAOKE RCT of 262 adults w/ Knee OA (w/ MRI effusion/synovitis) Rx w/ placebo vs , 2 g/d of krill oil showed no significant benefit in pain VAS score, −19.9 [krill oil] vs −20.2 [placebo]. https://t.co/8QSZyzIVh9 https://t.co/WbSb2gcmHb
Dr. John Cush RheumNow ( View Tweet)
Upside/Downside of Steroids in Lupus Nephritis
A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis (LN) demonstrates both the benefits and harms to early glucocorticoid (GC) regimens on lupus outcomes.
https://t.co/6NR3obURAw https://t.co/YyYBg1TcYr
Dr. John Cush RheumNow ( View Tweet)
Disparities in SLE care: adult Medicare cohort study of 1,036 SLE pts found 39% saw a rheumatologist q 6 mos & 28% had serologic tests. Least disadvantaged quintile had higher visit-based retention, but decreased serologic testing (aOR 0.80) https://t.co/lGoriPIMqV https://t.co/JF0RWZxRoU
Dr. John Cush RheumNow ( View Tweet)
Best Selling US Drugs in 2023
11 Skyrizi $10.1 billion
10 Dupixent $11.5 b
9 Biktarvy $13.15 b
8 Mounjaro $13.16 b
7 Keytruda $15.4 b
6 Stelara $15.87 b
5 Jardiance $15.89 b
4 Trulicity $16.3 b
3 Eliquis $22.1 b
2 Humira $35.3 b
1 Ozempic $38.6 b https://t.co/tiEwqyTB6D https://t.co/xghijiRFtW
Dr. John Cush RheumNow ( View Tweet)
384 Psoriasis pts followed mean 33 mos, 56 (14.6%) developed new-onset PsA. 311/384 (81%) had arthralgia (subclinical PsA) & 9.4% got PsA within 12 mos (23% by 36%). Subclinical more likely than PSO to get PsA (OR 11.7) https://t.co/D7n3ZpJURH https://t.co/vJcFgRcbx4
Dr. John Cush RheumNow ( View Tweet)
NON-treatment of 18,318 VA pts (RA, SpA, PsA) = 41% not Rx DMARDs w/in 12 mos of Dx. Signif higher odds if Black (HR 1.13), Hispanic (1.14), Charlson Comorbidity ≥2 (1.15), opiate use (1.09). DMARD use ^ if married, w/ erosions, female MD, Rheum Dx https://t.co/TaYC27oIOz https://t.co/qjfAGI5L5g
Links:
Dr. John Cush RheumNow ( View Tweet)
Mayo Derm Study of 335 #SLE pts: 231 w/ skin manifestations. LE specific skin Dz signif assoc w/ photosensitivity, SM & U1RNP Abs. Pts w/ 2–4 mucocutaneous ACR criteria had less cytopenia & dsDNA Abs (P=0.004), but no assoc w/ systemic Dz https://t.co/f7PEerxKZw https://t.co/9kRW724cPq
Dr. John Cush RheumNow ( View Tweet)
Full read review of the benefits & impact of hydroxychloroquine in #SLE. Benefits on:
- T cells, cytokines, TLR signaling
- VTE prevention
- Decr CV risks
- Glucose & lipid benefits
- Pregnancy
https://t.co/z9cooQwZux https://t.co/QumKoHgQDY
Dr. John Cush RheumNow ( View Tweet)
FAERS retrospective, safety study of JAKi use in 75K RA pts (52K Tofa; 21K Upa, 2.2K Bari vs bDMARDs) found JAKi had incr risk of VTE (adj ROR=2.11), CVA (ROR=1.25), IHD (1.23), edema(1.22), & tachyarrhythmias (1.15) https://t.co/Bvds4C66Nq https://t.co/Xmu8g35MXR
Links:
Dr. John Cush RheumNow ( View Tweet)
Brazilian Registry of Spondyloarthritis study of 1096 SpA pts, found 73% HLA-B27 positivity. B27+ signif assoc w/ males, earlier onset/Dx, uveitis, +FHx. B27 negativity assoc w/ psoriasis, higher peripheral arthritis/disease activity, worse QOL, mobility https://t.co/ousSetEnrt https://t.co/ezSgHro8sQ
Dr. John Cush RheumNow ( View Tweet)
MarketScan Claims & Medicaid study of incident AS, PsA, or RA (2010–2017) that Opioid use was highly prevalent in AS (36%), PsA (30%), & RA (44%) in the year prior to Dx & during the 1st Yr. Is this PCP or Rheumatologist mismanagement? https://t.co/YsCOLZUCfS https://t.co/b33uNg6Ucx
Dr. John Cush RheumNow ( View Tweet)
Insurance claims data studied 7580 newly Dx RA (2018-2020) - 1998 tofacitinib vs 5582 adalimumab. After propensity matching, dyslipidemia was signif. higher w/ TOFA (HR 1.25), BUT no differences in MACE (HR 0.995) or all-cause mortality (HR, 1.4; NS) https://t.co/ZJ7uHWTycS https://t.co/A6tSm4RipS
Dr. John Cush RheumNow ( View Tweet)